Supporting oncology professionals through education

The content on this site is intended for healthcare professionals only

Videos [3406]

Integration of DNA and RNA investigations in clinical trials: A laboratory...

Brandon Young - Bowden WIN Precision Oncology Laboratory, Murrieta, USA

Integration of DNA and RNA investigations in clinical trials: A laboratory challenge ( Brandon Young - Bowden WIN Precision Oncology Laboratory, Murrieta, USA )

Comment: POLO III trial for metastatic pancreatic cancer

Prof Heinz-Josef Lenz - USC Norris Comprehensive Cancer Center, Los Angeles, USA

Comment: POLO III trial for metastatic pancreatic cancer ( Prof Heinz-Josef Lenz - USC Norris Comprehensive Cancer Center, Los Angeles, USA )

Getting high level care to low and middle income countries

Dr Eduardo Cazap, Dr Clifford Hudis

Getting high level care to low and middle income countries ( Dr Eduardo Cazap, Dr Clifford Hudis )

Dasatinib-blinatumomab combination for the front-line treatment of adult Ph...

Prof Robin Foa - University of Rome, Rome, Italy

Dasatinib-blinatumomab combination for the front-line treatment of adult Ph-positive ALL patients ( Prof Robin Foa - University of Rome, Rome, Italy )

Dose escalation of REGN1979 in patients with relapsed and refractory B-NHL

Prof Max Topp - University of Würzburg, Würzburg, Germany

$Dose escalation of REGN1979 in patients with relapsed and refractory B-NHL ( Prof Max Topp - University of Würzburg, Würzburg, Germany )$

CD-19 mutation frequency after blinatumomab treatment is lower than after CAR T...

Dr Michaela Kotrova - Universitätsklinikum Schleswig-Holstein, Kiel, Germany

CD-19 mutation frequency after blinatumomab treatment is lower than after CAR T-cell therapy ( Dr Michaela Kotrova - Universitätsklinikum Schleswig-Holstein, Kiel, Germany )

Multiple myeloma science from EHA 2019

Prof Mohamad Mohty - Saint-Antoine Hospital, Paris, France

Multiple myeloma science from EHA 2019 ( Prof Mohamad Mohty - Saint-Antoine Hospital, Paris, France )

Controlling CRS-related coagulopathy improves the safety of CAR T-cell therapy...

Dr Heng Mei - Huazhong University of Science and Technology, Wuhan, China

Controlling CRS-related coagulopathy improves the safety of CAR T-cell therapy for MM ( Dr Heng Mei - Huazhong University of Science and Technology, Wuhan, China )

ICARIA results: Treating RRMM patients with isatuximab, pomalidomide and low...

Prof Paul Richardson - Dana-Farber Cancer Institute, Boston, USA

ICARIA results: Treating RRMM patients with isatuximab, pomalidomide and low-dose dexamethasone ( Prof Paul Richardson - Dana-Farber Cancer Institute, Boston, USA )

HORIZON update: Using melflufen to treat RRMM patients refractory to...

Prof Paul Richardson - Dana-Farber Cancer Institute, Boston, USA

$HORIZON update: Using melflufen to treat RRMM patients refractory to daratumumab and/or pomalidomide ( Prof Paul Richardson - Dana-Farber Cancer Institute, Boston, USA )$

Safety and efficacy of escalating doses of Hu5F9-G4 with rituximab in patients...

Dr Mark Roschewski - National Cancer Institute, Bethesda, USA

Safety and efficacy of escalating doses of Hu5F9-G4 with rituximab in patients with R/R DLBCL and indolent lymphoma ( Dr Mark Roschewski - National Cancer Institute, Bethesda, USA )

CLL12 trial: Ibrutinib in previously untreated, asymptomatic early-stage CLL

Dr Othman Al-Sawaf - University of Cologne, Cologne, Germany

CLL12 trial: Ibrutinib in previously untreated, asymptomatic early-stage CLL ( Dr Othman Al-Sawaf - University of Cologne, Cologne, Germany )

More from ecancer